Walleye Capital LLC Increases Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Walleye Capital LLC raised its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 49.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 383,591 shares of the biopharmaceutical company’s stock after buying an additional 127,003 shares during the period. Walleye Capital LLC owned about 0.36% of Intra-Cellular Therapies worth $32,038,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ITCI. GAMMA Investing LLC increased its holdings in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 240 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies in the fourth quarter valued at about $96,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $97,000. Covestor Ltd raised its position in shares of Intra-Cellular Therapies by 15.9% during the 4th quarter. Covestor Ltd now owns 2,099 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 288 shares during the last quarter. Finally, Barlow Wealth Partners Inc. acquired a new position in shares of Intra-Cellular Therapies during the 4th quarter worth about $184,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

ITCI stock opened at $131.87 on Monday. The firm has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.98. The firm’s 50 day moving average price is $130.29 and its 200-day moving average price is $104.37.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Leerink Partnrs lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Piper Sandler reaffirmed a “neutral” rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, StockNews.com started coverage on shares of Intra-Cellular Therapies in a research report on Sunday. They issued a “hold” rating for the company. Eleven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $106.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.